FDA approves daraxonrasib for patients with metastatic pancreatic cancer

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to other parts of the body and continued to progress despite previous treatment.

Read Original Copy